A phase I, open-label, multi-center, dose escalation study...

Annals of Oncology 2016 / 10 Vol. 27; Iss. suppl_6

A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

Bauer, S., Demetri, G., Jeay, S., Dummer, R., Guerreiro, N., Tan, D.S., Kumar, A., Meille, C., Van Bree, L., Halilovic, E., Wuerthner, J.U., Cassier, P.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw368.09
Date:
October, 2016
File:
PDF, 39 KB
english, 2016
Conversion to is in progress
Conversion to is failed